InvestSMART

Innate Immunotherapeutics Limited (ASX: IIL) - Announcements

Current share price for IIL : $0.360 0.02 (5.88%)+

ASX company news and announcements for Innate Immunotherapeutics Limited (IIL) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Innate Immunotherapeutics Limited (IIL) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Innate Immunotherapeutics Limited (IIL), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Innate Immunotherapeutics Limited (IIL)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
- Extracts Re MIS416 Accepted at American Academy Neurologists 7 Mar 2017 11:01AM $0.630 $0.360 fallen by 42.86%
- Phase 2B Trial of MIS416 on Schedule to Complete April 2017 28 Feb 2017 8:28AM $0.590 $0.360 fallen by 38.98%
- Change of Director's Interest Notice - Simon Wilkinson 21 Feb 2017 6:31PM $0.685 $0.360 fallen by 47.45%
- Appendix 3B - Exercise of Employee Options 20 Feb 2017 6:15PM $0.780 $0.360 fallen by 53.85%
- TOV: IIL Panel Declines to Conduct Proceedings 20 Feb 2017 9:35AM $0.795 $0.360 fallen by 54.72%
- Innate Immunotherapeutics Limited Panel Receives Application 15 Feb 2017 10:28AM $0.875 $0.360 fallen by 58.86%
- Appendix 3B - Exercise of Employee Options 6 Feb 2017 1:00PM $0.990 $0.360 fallen by 63.64%
- Appendix 4C - Dec 2016 Quarter Statement of Cashflows 31 Jan 2017 8:27AM $0.780 $0.360 fallen by 53.85%
- Response to ASX Price Query 27 Jan 2017 8:57AM $1.770 $0.360 fallen by 79.66%
- Ceasing to be a substantial holder from AEF 24 Jan 2017 1:48PM $1.725 $0.360 fallen by 79.13%
- Change in substantial shareholding from AEF 19 Jan 2017 4:03PM $1.550 $0.360 fallen by 76.77%
- Biotech Showcase Presentation 10 Jan 2017 8:53AM $1.050 $0.360 fallen by 65.71%
- Response to Price Query 30 Dec 2016 2:08PM $1.080 $0.360 fallen by 66.67%
- Change Director's Interest - Wilkinson Loyalty Rights Expire 19 Dec 2016 5:09PM $0.830 $0.360 fallen by 56.63%
- Change Director's Interest - Collins Loyalty Rights Expire 19 Dec 2016 5:08PM $0.830 $0.360 fallen by 56.63%
- Change of Director's Interest - M Quinn Loyalty Right Expire 19 Dec 2016 5:08PM $0.830 $0.360 fallen by 56.63%
- Loyalty Rights Expire 19 Dec 2016 10:01AM $0.840 $0.360 fallen by 57.14%
- Change in substantial holding from AEF 2 Dec 2016 11:45AM $0.930 $0.360 fallen by 61.29%
- App 4D - Half Yearly Report and Accounts HY ended 30 Sep 16 29 Nov 2016 1:34PM $0.770 $0.360 fallen by 53.25%
- Presentation to ASX FNN CEO Sessions Investor Forum 22 Nov 2016 8:29AM $0.690 $0.360 fallen by 47.83%
- Phase 2B Update - Patients Wanting Access to Drug Post Trial 7 Nov 2016 9:19AM $0.560 $0.360 fallen by 35.71%
- Appendix 4C - Quarterly Cashflows Report - Sept 2016 Qtr 31 Oct 2016 3:52PM $0.710 $0.360 fallen by 49.30%
- Change in substantial holding from AEF 24 Oct 2016 4:06PM $0.730 $0.360 fallen by 50.68%
- Change in substantial holding from AEF 14 Oct 2016 1:03PM $0.600 $0.360 fallen by 40%
- Section 708A - Cleansing Notice Final Allotment Placement 2 26 Sep 2016 12:41AM $0.500 $0.360 fallen by 28%

76 - 100 of 191 results

Page 4 of 8

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.